Patient leaflet - Integrilin 2 mg/ml solution for injection
1. WHAT INTEGRILIN IS AND WHAT IT IS USED FOR
Integrilin is an inhibitor of platelet aggregation. This means that it helps to prevent blood clots from forming.
It is used in adults with manifestation of severe coronary insufficiency defined as spontaneous and recent chest pain with electrocardiographic abnormalities or biological changes. It is usually given with aspirin and unfractionated heparin.
2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN INTEGRILIN
You must not be given Integrilin:
- if you are allergic to eptifibatide or any of the other ingredients of this medicine (listed in section 6).
if you have recently had bleeding from your stomach, intestines, bladder or other organs, for example if you
have seen abnormal blood in your stool or urine (except from menstrual bleeding) in the past 30 days.
if you have had a stroke within the past 30 days or any haemorrhagic stroke (also, be sure your doctor
knows if you ever had a stroke).
- if you have had a brain tumour or a condition that affects the blood vessels around the brain.
- if you had a major operation or severe injury during the past 6 weeks.
- if you have or have had bleeding problems.
- if you have or have had difficulty with your blood clotting or a low blood platelet count.
- if you have or have had severe hypertension (high blood pressure).
- if you have or have had severe kidney or liver problems.
- if you have been treated with another medicine of the same type as Integrilin.
Please tell your doctor if you have had any of these conditions. If you have any questions, ask your doctor or hospital pharmacist or nurse.
Take special care with Integrilin:
- Integrilin is recommended for use only in adult, hospitalised patients in coronary care units.
Integrilin is not intended for use in children or adolescents less than 18 years of age.
Before and during your treatment with Integrilin, samples of your blood will be tested as a safety measure
to limit the possibility of unexpected bleeding.
During use of Integrilin, you will be checked carefully for any signs of unusual or unexpected bleeding.
Other medicines and Integrilin
To avoid the possibility of interactions with other medicines please tell your doctor or hospital pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. Particularly:
- blood thinners (oral anticoagulants) or
medicines that prevent blood clots, including warfarin, dipyridamole, ticlopidine, aspirin (except those
that you may be given as part of Integrilin treatment).
Pregnancy and breast-feeding
Integrilin is not usually recommended for use during pregnancy. Tell your doctor if you are pregnant, think you might be pregnant or are planning to have a baby. Your doctor will weigh up the benefit to you against the risk to your baby of using Integrilin while you are pregnant.
If you are breast-feeding a baby, breast-feeding should be interrupted during the treatment period.
Integrilin contains sodium
This medicine contains 13.8 mg sodium (main component of cooking/table salt) in each 10 ml vial. This is
equivalent to 0.69% of the recommended maximum daily dietary intake of sodium for an adult.
3. HOW TO USE INTEGRILIN
Integrilin is given into the vein by direct injection followed by an infusion (drip solution). The dose given is based on your weight. The recommended dose is 180 microgram/kg administered as a bolus (rapid intravenous injection), followed by an infusion (drip solution) of 2 microgram/kg/minute for up to 72 hours. If you have kidney disease, the infusion dose may be reduced to 1 microgram/kg/minute.
If percutaneous coronary intervention (PCI) is performed during Integrilin therapy, the intravenous solution may be continued for up to 96 hours.
You must also be given doses of aspirin and heparin (if not contraindicated in your case).
If you have any further questions on the use of this product, ask your doctor or hospital pharmacist or nurse.
4. POSSIBLE SIDE EFFECTS
Like all medicines, this medicine can cause side effects, although not everybody gets them. Very common side effects
These may affect more than 1 in 10 people
minor or major bleeding, (for example, blood in urine, blood in stool, vomiting blood, or bleeding with
surgical procedures).
- anaemia (decreased number of red blood cells).
Common side effects
These may affect up to 1 in 10 people
- inflammation of a vein.
Uncommon side effects
These may affect up to 1 in 100 people
- reduction in the number of platelets (blood cells necessary for blood clotting).
- reduced blood flow to the brain.
Very rare side effects
These may affect up to 1 in 10,000 people
- serious bleeding (for example, bleeding inside the abdomen, inside the brain, and into the lungs)
- fatal bleeding.
- severe reduction in the number of platelets (blood cells necessary for blood clotting).
- skin rash (such as hives).
- sudden, severe allergic reaction.
If you notice any signs of bleeding, notify your doctor or hospital pharmacist or nurse immediately. Very rarely, bleeding has become severe and even fatal. Safety measures to prevent this from happening include blood tests and careful checking by the healthcare professionals taking care of you.
If you develop severe allergic reaction or hives, notify your doctor or hospital pharmacist or nurse immediately.
Other events that may occur in patients, who require this type of treatment, include those that are related to the condition you are having treated, such as rapid or irregular heartbeat, low blood pressure, shock or cardiac arrest.
Reporting of side effects
If you get any side effects, talk to your doctor, hospital pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
5. HOW TO STORE INTEGRILIN
Keep this medicine out of the sight and reach of children
Do not use this medicine after the expiry date (EXP) stated on the package and the vial. The expiry date refers to the last day of that month.
Store in a refrigerator (2°C – 8°C).
Keep the vial in the outer package in order to protect from light. However, protection of Integrilin solution from light is not necessary during administration.
Before using, the vial contents should be inspected.
Integrilin should not be used if it is noticed that particulate matter or discoloration is present.
Any unused medicine after opening should be thrown away.
Do not throw away any medicines via wastewater or household waste. Ask your hospital pharmacist how to throw away medicines you no longer use.
6. CONTENTS OF THE PACK AND OTHER INFORMATION
What Integrilin contains
- The active substance is eptifibatide. Each ml of solution for injection contains 2 mg of eptifibatide. One vial of 10 ml solution for injection contains 20 mg of eptifibatide.
- The other ingredients are citric acid monohydrate, sodium hydroxide and water for injections.
What Integrilin looks like and contents of the pack
Integrilin solution for injection: 10 ml vial, pack of one vial.
The clear, colourless solution is contained in a 10 ml glass vial, which is closed with a butyl rubber stopper and sealed with a crimped aluminium seal.
Marketing Authorisation Holder and manufacturer
Marketing Authorisation Holder:
GlaxoSmithKline UK Limited
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Manufacturer:
Glaxo Operations UK Ltd., (Trading as Glaxo Wellcome Operations), Harmire Road, Barnard Castle, Co. Durham, DL12 8DT, United Kingdom
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
United Kingdom
GlaxoSmithKline UK Ltd
Tel: + 44 (0)800 221441
customercontactuk@gsk.com
This leaflet was last revised in January 2021
Other formats
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK Only)
Please be ready to give the following information:
Product name – Integrilin 2 mg/ml solution for injection
Reference number – 19494/0275
This is a service provided by the Royal National Institute of Blind People.
Trademarks are owned by or licenced to the GSK group of companies. © 2022 GSK group of companies or its licensor.
62000000080447
IMPORTANT GSK LOC is responsible to
and complete.
GSK SDC is responsible for site technical requirements and pre-press suitability.
GSK Market is responsible to advise SDC when changes required impact the following:
Formulation Tablet embossing Storage conditions
Shelf Life
NOTE TO MARKET
Local approvers must ensure that trade mark and copyright statements included in the brief comply with guidance provided by
Legal: Global Trade Marks.
Manufacturing Site Number:
62000000080447
Manufacturing Site(s):
GSK_BARNARD CASTLE_UNITED KINGDOM
JMF302
Product Market Trade Name:
INTEGRILIN
Approving Market(s):
United Kingdom excluding Northern Ireland-XU
Material Spec: (Do NOT include version number):
N/A
N/A
Colour Standard Reference:
N/A
Material Type:
N/A N/A
9.0pt
9.0pt
Leading:
10.5pt
Horizontal Scale:
100%
Microtext:
N
1
0
Additional Info (1):
N/A
Additional Info (2):
N/A
Additional Info (3):
N/A
200 mm Measuring Bar
If an e-banner DOES NOT appear on the top of this document, THEN this document has NOT been printed from the Harmony system. Artwork copyright is the property of the GSK Group of Companies. All suppliers providing a service to GSK for printed components of any description must ensure that they have a licence for all fonts / software used in conjunction with GSK artwork. The distribution and use of fonts / software without a licence constitutes an intellectual property infringement. GSK will not accept any liability for the breach of third party intellectual property rights by printed component suppliers. The GSK certification / audit process requires suppliers to declare that they do not use unlicensed fonts / software and may require the supplier to produce evidence of such licence to GSK.
Project: CO-0046879
Site Code: 62000000080447
Document: PPC-0029558 Version: 3
Operator: SR185592 Date/Time Created: 23.Nov.2022 17:27 GMT
e-Banner